Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). METHODS: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 cou...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Reardon, D A, Dresemann, G, Taillibert, S, Campone, M, van den Bent, M, Clement, P, Blomquist, E, Gordower, L, Schultz, H, Raizer, J, Hau, P, Easaw, J, Gil, M, Tonn, J, Gijtenbeek, A, Schlegel, U, Bergstrom, P, Green, S, Weir, A, Nikolova, Z
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2009
Onderwerpen:
Clinical Study
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2795431/
https://ncbi.nlm.nih.gov/pubmed/19904263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605411
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items